Castle Creek Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Castle Creek Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Castle Creek Pharmaceuticals: 7 sponsored US clinical trials, none currently recruiting.

Castle Creek Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epidermolysis Bullosa (EB), with 1 trials.

Upper-quartile sponsor footprint

Castle Creek Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 1

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

NCT03472287
COMPLETED Phase 1

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

NCT03472547
COMPLETED Phase 1

A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

NCT03472534
COMPLETED Phase 1

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

NCT03473197
COMPLETED Phase 1

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

NCT03473184
COMPLETED Phase 2

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

NCT03389308
TERMINATED Phase 2

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

NCT03154333

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2

Therapeutic Areas

Epidermolysis Bullosa (EB) 1
Epidermolysis Bullosa Simplex 1
Junctional Epidermolysis Bullosa 1
Dystrophic Epidermolysis Bullosa 1
Healthy 1

How the Castle Creek Pharmaceuticals early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Epidermolysis Bullosa (EB) (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Castle Creek Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Castle Creek Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Castle Creek Pharmaceuticals3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Castle Creek Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Castle Creek Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Castle Creek Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of Castle Creek Pharmaceuticals or any single study.

  • None of Castle Creek Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Epidermolysis Bullosa (EB) is the condition Castle Creek Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epidermolysis Bullosa (EB) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Castle Creek Pharmaceuticals pipeline card: 7 registered trials from official public datasets.Report a data error.